Learn More Semaglutide Single-receptor (GLP-1) FDA-approved branded peer
Key Takeaways Retatrutide is an emerging medication for weight management and metabolic health that is expected to become more widely available around 2026
More commonly, people quote the Lancet Diabetes & Endocrinology paper stating that the proportion of lean mass loss relative to total weight loss was similar to other obesity treatments, and that these findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide But other obesity treatments is vague
Studies in elderly populations, who share some constipation mechanisms with GLP-1 users (slower transit, reduced food intake), showed significant improvements in bowel movement frequency
If you can't independently confirm who made your medication, you have no way to rule out counterfeit supply
It is also suitable for patients with mild insulin resistance who are non-diabetic or pre-diabetic, to provide mild appetite control and improve metabolic health
